Société des Industries Pharmaceutiques de Tunisie - (SIPHA) Stock Overview
Société des Industries Pharmaceutiques de Tunisie - S.A. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
SIPHA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Société des Industries Pharmaceutiques de Tunisie - S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.ت4.70 |
| 52 Week High | د.ت6.68 |
| 52 Week Low | د.ت3.45 |
| Beta | 0 |
| 1 Month Change | 0.86% |
| 3 Month Change | 25.00% |
| 1 Year Change | -23.08% |
| 3 Year Change | 40.30% |
| 5 Year Change | -16.96% |
| Change since IPO | -73.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| SIPHA | TN Pharmaceuticals | TN Market | |
|---|---|---|---|
| 7D | 0% | 3.5% | 1.7% |
| 1Y | -23.1% | 19.1% | 37.2% |
Return vs Industry: SIPHA underperformed the TN Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: SIPHA underperformed the TN Market which returned 37.2% over the past year.
Price Volatility
| SIPHA volatility | |
|---|---|
| SIPHA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in TN Market | 6.0% |
| 10% least volatile stocks in TN Market | 2.9% |
Stable Share Price: SIPHA's share price has been volatile over the past 3 months compared to the TN market.
Volatility Over Time: Insufficient data to determine SIPHA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Anis Klouz | www.siphat.rns.tn |
Société des Industries Pharmaceutiques de Tunisie - S.A. engages in the research, development, manufacture, packaging, and marketing of pharmaceutical products for human use in Tunisia and internationally. It provides rheumatology drugs, such as MYORELAX, NIFLUMIC, and ALGESAL SURACTIVE; stomatology drugs, including HEXABAIN; and ANALGAN CODEINE 300mg/25mg indicated for the symptomatic treatment of moderate and intense pain. The company was founded in 1989 and is headquartered in Ben Arous, Tunisia.
Société des Industries Pharmaceutiques de Tunisie - S.A. Fundamentals Summary
| SIPHA fundamental statistics | |
|---|---|
| Market cap | د.ت8.46m |
| Earnings (TTM) | -د.ت17.10m |
| Revenue (TTM) | د.ت20.23m |
Is SIPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIPHA income statement (TTM) | |
|---|---|
| Revenue | د.ت20.23m |
| Cost of Revenue | د.ت11.03m |
| Gross Profit | د.ت9.19m |
| Other Expenses | د.ت26.30m |
| Earnings | -د.ت17.10m |
Last Reported Earnings
Jun 30, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SIPHA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 06:38 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Société des Industries Pharmaceutiques de Tunisie - S.A. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kais Kriaa | AlphaMena |
| Rim Ben Salah Gharbi | AlphaMena |
| Ghada Jendoubi | AlphaMena |